Biomica Ltd. | MedPath

Microbiome Therapeutics Pipeline Expands with 180+ Novel Therapies in Development Across 140 Companies

3 months ago

• The microbiome therapeutics landscape shows remarkable growth with over 140 companies actively developing 180+ pipeline drugs, spanning various disease areas and therapeutic approaches. • Recent clinical advances include promising results from MaaT Pharma's Phase 3 ARES study for GI-aGvHD and Vedanta Biosciences' Phase 2 CONSORTIUM study of VE303 for recurrent C. difficile infection. • Multiple innovative approaches are being pursued, including live biotherapeutic products, with companies like Microbiotica's MB097 showing potential in enhancing immunotherapy responses in cancer treatment.